<DOC>
	<DOCNO>NCT02257216</DOCNO>
	<brief_summary>The primary study objective evaluate efficacy Vayarin ADHD adult .</brief_summary>
	<brief_title>Vayarin® Medical Food Study Adults With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Male female age 1860 inclusive . 2 . Primary diagnosis ADHD 3 . At least 50 % sample abnormal score Emotional Control subscale BRIEFA ≥65 . 4 . AISRS total score ≥ 24 5 . CGIS ≥4 ( moderately ill bad ) . 6 . Subjects ongoing psychotherapy allow , significant change frequency , type intensity therapy make course study participation per discretion principal investigator . The subject must psychotherapy least 4 week prior screen visit . 7 . Understands able , willing , likely fully comply study procedure restriction . 8 . Has give write informed consent participate study . 1 . BMI le than18.5 great 35 . 2 . Any underlying/ history current diagnosis systemic and/or metabolic disease ( e.g . diabetes , Crohn 's disease ) and/or neurological condition state may render subject illegible participate study assess medical history , physical exam , clinical lab evaluation . 3 . History uncontrolled hypertension rest systolic blood pressure &gt; 140mmHg diastolic blood pressure &gt; 90mmHg ( Subjects well control hypertension stable dose ( 2 month ) antihypertensives allow participate ) . 4 . Hamilton Anxiety Scale ( HAMA ) ≥ 17 ) . 5 . Hamilton Depression scale ( HAMD ≥ 13 ) . 6 . Major depression anxiety disorder focus treatment require take medication . 7 . A lifetime history psychosis bipolar disorder base clinicianadministered interview use Mini International Neuropsychiatric Interview ( M.I.N.I 7.0 ) . Subjects mild moderate form social phobia dysthymia , require treatment , allow . 8 . Has concurrent chronic unstable medical condition could confound result safety assessment , increase risk subject lead difficulty comply protocol . 9 . Subjects take medication CNS effect ( exclude subject discontinue medication least 2 week prior study stimulant 4 week SSRI , nonstimulants , alpha 2agonist ) . 10 . Subjects history two prior fail adequate trial ADHD treatment due adverse event . 11 . Use dietary supplement potential CNS effect , include omega3 supplement , 30 day study initiation throughout study . 12 . Clinical history cognitive impairment judgment investigator . 13 . Pregnant breastfeeding subject . Women childbearing potential must negative pregnancy test perform screen visit prior randomization . Women childbearing potential must agree use adequate birth control entire duration study . 14 . Subjects current ( within last 3 month ) DSMV diagnosis alcohol drug abuse dependence ( exclude nicotine ) . 15 . Known history allergic reaction sensitivity marine product ( fish seafood ) , soy . 16 . Has take investigational drug take part clinical trial within 30 day prior screen . 17 . Any reason , opinion investigator , prevents subject participate study compromise subject safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>